Concept and gestation:
- Scientific founders can sometimes forget that they are running a business and not a lab. It is important to use the seed capital to drive the enterprise, and not just the science, forward.
- Conversely, it is possible to rush a compound from discovery into the next phase - preclinical and expensive IND- (investigative new drug) enabling studies - without adequate understanding of the basic biology underlying the putative action of the compound, thus increasing the risk of an early failure.
- Inadequate management of dilution.
- Inattention to the need for skilled business leadership in addition to gifted scientific skills.
- A rush into a premature licensing transaction with a legacy pharmaceutical company, resulting in loss of control of the compound and an inadequate financial return.
- Designing and running clinical trials based on...
Have a comment? E-mail us at firstname.lastname@example.org
Sam Hall is an Associate and Alastair Wood is Managing Director at Symphony Capital New York, NY.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!